Bupropion SR for relapse prevention: A "slips-allowed" analysis

Michael J. Durcan; J. Andrew Johnston; Jonathan White; David Gonzales; David P.L. Sachs; Nancy Rigotti; Raymond Niaura

doi:10.5993/AJHB.28.5.8

Bupropion SR for relapse prevention: A "slips-allowed" analysis

Michael J. Durcan, J. Andrew Johnston, Jonathan White, David Gonzales, David P.L. Sachs, Nancy Rigotti, Raymond Niaura

Global Public Health

Research output: Contribution to journal › Article › peer-review

Abstract

Objective: To assess the efficacy of bupropion SR on smoking abstinence using a "slips allowed" analysis. Methods: Retrospective analysis, which did not consider brief episodic "slips" as a return to regular smoking, of data from a multicenter, randomized, double- blind, placebo-controlled relapse prevention study. Results: Using a slips-allowed analysis, median time to relapse on bupropion SR was 65 weeks versus 30 weeks on placebo. This is compared to 32 and 20 weeks, respectively, using a traditional analysis not allowing for slips. Conclusion: Bupropion SR is efficacious for the prevention of smoking relapse. A slips-allowed analysis may provide a more clinically relevant assessment of efficacy.

Original language	English (US)
Pages (from-to)	456-463
Number of pages	8
Journal	American Journal of Health Behavior
Volume	28
Issue number	5
DOIs	https://doi.org/10.5993/AJHB.28.5.8
State	Published - 2004

Keywords

Bupropion
Relapse prevention
Slips allowed analysis
Smoking cessation

ASJC Scopus subject areas

Health(social science)
Social Psychology
Public Health, Environmental and Occupational Health

Access to Document

10.5993/AJHB.28.5.8

Cite this

@article{7d1c1b8863ec4c09836287c0d1f551bd,

title = "Bupropion SR for relapse prevention: A {"}slips-allowed{"} analysis",

abstract = "Objective: To assess the efficacy of bupropion SR on smoking abstinence using a {"}slips allowed{"} analysis. Methods: Retrospective analysis, which did not consider brief episodic {"}slips{"} as a return to regular smoking, of data from a multicenter, randomized, double- blind, placebo-controlled relapse prevention study. Results: Using a slips-allowed analysis, median time to relapse on bupropion SR was 65 weeks versus 30 weeks on placebo. This is compared to 32 and 20 weeks, respectively, using a traditional analysis not allowing for slips. Conclusion: Bupropion SR is efficacious for the prevention of smoking relapse. A slips-allowed analysis may provide a more clinically relevant assessment of efficacy.",

keywords = "Bupropion, Relapse prevention, Slips allowed analysis, Smoking cessation",

author = "Durcan, {Michael J.} and Johnston, {J. Andrew} and Jonathan White and David Gonzales and Sachs, {David P.L.} and Nancy Rigotti and Raymond Niaura",

year = "2004",

doi = "10.5993/AJHB.28.5.8",

language = "English (US)",

volume = "28",

pages = "456--463",

journal = "American Journal of Health Behavior",

issn = "1087-3244",

publisher = "PNG Publications",

number = "5",

}

TY - JOUR

T1 - Bupropion SR for relapse prevention

T2 - A "slips-allowed" analysis

AU - Durcan, Michael J.

AU - Johnston, J. Andrew

AU - White, Jonathan

AU - Gonzales, David

AU - Sachs, David P.L.

AU - Rigotti, Nancy

AU - Niaura, Raymond

PY - 2004

Y1 - 2004

N2 - Objective: To assess the efficacy of bupropion SR on smoking abstinence using a "slips allowed" analysis. Methods: Retrospective analysis, which did not consider brief episodic "slips" as a return to regular smoking, of data from a multicenter, randomized, double- blind, placebo-controlled relapse prevention study. Results: Using a slips-allowed analysis, median time to relapse on bupropion SR was 65 weeks versus 30 weeks on placebo. This is compared to 32 and 20 weeks, respectively, using a traditional analysis not allowing for slips. Conclusion: Bupropion SR is efficacious for the prevention of smoking relapse. A slips-allowed analysis may provide a more clinically relevant assessment of efficacy.

AB - Objective: To assess the efficacy of bupropion SR on smoking abstinence using a "slips allowed" analysis. Methods: Retrospective analysis, which did not consider brief episodic "slips" as a return to regular smoking, of data from a multicenter, randomized, double- blind, placebo-controlled relapse prevention study. Results: Using a slips-allowed analysis, median time to relapse on bupropion SR was 65 weeks versus 30 weeks on placebo. This is compared to 32 and 20 weeks, respectively, using a traditional analysis not allowing for slips. Conclusion: Bupropion SR is efficacious for the prevention of smoking relapse. A slips-allowed analysis may provide a more clinically relevant assessment of efficacy.

KW - Bupropion

KW - Relapse prevention

KW - Slips allowed analysis

KW - Smoking cessation

UR - http://www.scopus.com/inward/record.url?scp=13244262595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13244262595&partnerID=8YFLogxK

U2 - 10.5993/AJHB.28.5.8

DO - 10.5993/AJHB.28.5.8

M3 - Article

C2 - 15482975

AN - SCOPUS:13244262595

SN - 1087-3244

VL - 28

SP - 456

EP - 463

JO - American Journal of Health Behavior

JF - American Journal of Health Behavior

IS - 5

ER -

Bupropion SR for relapse prevention: A "slips-allowed" analysis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this